Central and peripheral mechanisms of the NPY system in the regulation of bone and adipose tissue

Bone

Volumn 50, Issue 2, 2012, Pages 430-436

  Shi, Yan Chuan ^a   Baldock, Paul A ^a,b  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Adipose; Bone; Hypothalamus; Neuropeptide Y; Y receptors

Indexed keywords

G PROTEIN COUPLED RECEPTOR; NEUROPEPTIDE Y;

ADIPOCYTE; ADIPOSE TISSUE; BONE DEVELOPMENT; BONE MASS; BONE TISSUE; BRAIN FUNCTION; CALORIC INTAKE; CANCELLOUS BONE; CORTICAL BONE; ENERGY CONSERVATION; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMAN; HYPOTHALAMUS NUCLEUS; LIPOGENESIS; NONHUMAN; OSSIFICATION; PROTEIN FUNCTION; RECEPTOR GENE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; WEIGHT GAIN;

ADIPOSE TISSUE; BONE AND BONES; CENTRAL NERVOUS SYSTEM; HUMANS; NEUROPEPTIDE Y; PERIPHERAL NERVOUS SYSTEM; RECEPTORS, NEUROPEPTIDE Y;

EID: 84855896752     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2011.10.001     Document Type: Review

References (103)

1. Kanis J.A. An update on the diagnosis of osteoporosis. Curr Rheumatol Rep 2000, 2:62-66.
2. Hill J.O. Understanding and addressing the epidemic of obesity: an energy balance perspective. Endocr Rev 2006, 27:750-761.
3. Ribot C., Tremollieres F., Pouilles J.M., Bonneu M., Germain F., Louvet J.P. Obesity and postmenopausal bone loss: the influence of obesity on vertebral density and bone turnover in postmenopausal women. Bone 1987, 8:327-331.
4. Reid I.R., Plank L.D., Evans M.C. Fat mass is an important determinant of whole body bone density in premenopausal women but not in men. J Clin Endocrinol Metab 1992, 75:779-782.
5. Gilsanz V., Chalfant J., Mo A.O., Lee D.C., Dorey F.J., Mittelman S.D. Reciprocal relations of subcutaneous and visceral fat to bone structure and strength. J Clin Endocrinol Metab 2009, 94:3387-3393.
6. Clark E.M., Ness A.R., Tobias J.H. Adipose tissue stimulates bone growth in prepubertal children. J Clin Endocrinol Metab 2006, 91:2534-2541.
7. Timpson N.J., Sayers A., Davey-Smith G., Tobias J.H. How does body fat influence bone mass in childhood? A Mendelian randomization approach. J Bone Miner Res 2009, 24:522-533.
8. Sayers A., Timpson N.J., Sattar N., Deanfield J., Hingorani A.D., Davey-Smith G., et al. Adiponectin and its association with bone mass accrual in childhood. J Bone Miner Res 2010, 25:2212-2220.
9. Confavreux C.B., Levine R.L., Karsenty G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol Cell Endocrinol 2009, 310:21-29.
10. Rosen C.J., Klibanski A. Bone, fat, and body composition: evolving concepts in the pathogenesis of osteoporosis. Am J Med 2009, 122:409-414.
11. Rosen C.J. Leptin's RIGHT turn to the brain stem. Cell Metab 2009, 10:243-244.
12. Reid I.R. Relationships between fat and bone. Osteoporos Int 2008, 19:595-606.
13. Nguyen N.D., Pongchaiyakul C., Center J.R., Eisman J.A., Nguyen T.V. Identification of high-risk individuals for hip fracture: a 14-year prospective study. J Bone Miner Res 2005, 20:1921-1928. Epub 2005 May 31.
14. Nguyen N.D., Pongchaiyakul C., Center J.R., Eisman J.A., Nguyen T.V. Abdominal fat and hip fracture risk in the elderly: the Dubbo Osteoporosis Epidemiology Study. BMC Musculoskelet Disord 2005, 6:11.
15. De Laet C., Kanis J.A., Oden A., Johanson H., Johnell O., Delmas P., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 2005, 16:1330-1338.
16. Nguyen T.V., Sambrook P.N., Eisman J.A. Bone loss, physical activity, and weight change in elderly women: the Dubbo Osteoporosis Epidemiology Study. J Bone Miner Res 1998, 13:1458-1467.
17. Bliuc D., Nguyen N.D., Milch V.E., Nguyen T.V., Eisman J.A., Center J.R. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009, 301:513-521.
18. Nguyen N.D., Center J.R., Eisman J.A., Nguyen T.V. Bone loss, weight loss, and weight fluctuation predict mortality risk in elderly men and women. J Bone Miner Res 2007, 22:1147-1154.
19. Belfrage P., Fredrikson G., Olsson H., Stralfors P. Molecular mechanisms for hormonal control of adipose tissue lipolysis. Int J Obes 1985, 9(Suppl 1):129-135.
20. Driessler F, Baldock PA. Hypothalamic regulation of bone. J Mol Endocrinol 45: 175-181.
21. Zengin A, Zhang L, Herzog H, Baldock PA, Sainsbury A. Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat. Trends Endocrinol Metab 21: 411-418.
22. Baraban S.C. Neuropeptide Y and limbic seizures. Rev Neurosci 1998, 9:117-128.
23. Lin S., Boey D., Herzog H. NPY and Y receptors: lessons from transgenic and knockout models. Neuropeptides 2004, 38:189-200.
24. Ekblad E., Edvinsson L., Wahlestedt C., Uddman R., Hakanson R., Sundler F. Neuropeptide Y co-exists and co-operates with noradrenaline in perivascular nerve fibers. Regul Pept 1984, 8:225-235.
25. Baldock P.A., Allison S.J., Lundberg P., Lee N.J., Slack K., Lin E.J., et al. Novel role of Y1 receptors in the coordinated regulation of bone and energy homeostasis. J Biol Chem 2007, 282:19092-19102.
26. Kuo L.E., Kitlinska J.B., Tilan J.U., Li L., Baker S.B., Johnson M.D., et al. Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome. Nat Med 2007, 13:803-811.
27. Yang K., Guan H., Arany E., Hill D.J., Cao X. Neuropeptide Y is produced in visceral adipose tissue and promotes proliferation of adipocyte precursor cells via the Y1 receptor. FASEB J 2008, 22:2452-2464.
28. Parker R.M., Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 1999, 11:1431-1448.
29. Blomqvist A.G., Herzog H. Y-receptor subtypes-how many more?. Trends Neurosci 1997, 20:294-298.
30. Naveilhan P., Neveu I., Arenas E., Ernfors P. Complementary and overlapping expression of Y1, Y2 and Y5 receptors in the developing and adult mouse nervous system. Neuroscience 1998, 87:289-302.
31. Lee N.J., Doyle K.L., Sainsbury A., Enriquez R.F., Hort Y.J., Riepler S.J., et al. Critical role for Y1 receptors in mesenchymal progenitor cell differentiation and osteoblast activity. J Bone Miner Res 2010, 25:1736-1747.
32. Lundberg P., Allison S.J., Lee N.J., Baldock P.A., Brouard N., Rost S., et al. Greater bone formation of Y2 knockout mice is associated with increased osteoprogenitor numbers and altered Y1 receptor expression. J Biol Chem 2007, 282:19082-19091.
33. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
34. Allison S., Baldock P., Enriquez R., Lin E., During M., Gardiner E., et al. Critical interplay between neuropeptide Y and sex steroid pathways in bone and adipose tissue homeostasis. J Bone Miner Res 2008.
35. Baldock P.A., Sainsbury A., Allison S., Lin E.J., Couzens M., Boey D., et al. Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. J Bone Miner Res 2005, 20:1851-1857.
36. Baldock P.A., Lee N.J., Driessler F., Lin S., Allison S., Stehrer B., et al. Neuropeptide Y knockout mice reveal a central role of NPY in the coordination of bone mass to body weight. PLoS One 2009, 4:e8415.
37. Elefteriou F., Takeda S., Liu X., Armstrong D., Karsenty G. Monosodium glutamate-sensitive hypothalamic neurons contribute to the control of bone mass. Endocrinology 2003, 144:3842-3847.
38. Karl T., Duffy L., Herzog H. Behavioural profile of a new mouse model for NPY deficiency. Eur J Neurosci 2008, 28:173-180.
39. Allison S.J., Baldock P.A., Herzog H. The control of bone remodeling by neuropeptide Y receptors. Peptides 2007, 28:320-325.
40. Fetissov S.O., Byrne L.C., Hassani H., Ernfors P., Hokfelt T. Characterization of neuropeptide Y Y2 and Y5 receptor expression in the mouse hypothalamus. J Comp Neurol 2004, 470:256-265.
41. Parker R.M.C., Herzog H. Regional distribution of Y-receptor subtype mRNAs in rat brain. Eur J Neurosci 1999, 11:1431-1448.
42. Lin S., Boey D., Couzens M., Lee N., Sainsbury A., Herzog H. Compensatory changes in [125I]-PYY binding in Y receptor knockout mice suggest the potential existence of further Y receptor(s). Neuropeptides 2005, 39:21-28.
43. Broberger C., Landry M., Wong H., Walsh J.N., Hokfelt T. Subtypes Y1 and Y2 of the neuropeptide Y receptor are respectively expressed in pro-opiomelanocortin- and neuropeptide-Y-containing neurons of the rat hypothalamic arcuate nucleus. Neuroendocrinology 1997, 66:393-408.
44. King P.J., Williams G., Doods H., Widdowson P.S. Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release. Eur J Pharmacol 2000, 396:R1-R3.
45. Shi Y.C., Lin S., Castillo L., Aljanova A., Enriquez R.F., Nguyen A.D., et al. Peripheral-specific Y2 receptor knockdown protects mice from high-fat diet-induced obesity. Obesity (Silver Spring) 2011.
46. Playford R.J., Cox H.M. Peptide YY and neuropeptide Y: two peptides intimately involved in electrolyte homeostasis. Trends Pharmacol Scin 1996, 17:436-438.
47. Koda S., Date Y., Murakami N., Shimbara T., Hananda T., Toshinai K., et al. The role of the vagal nerve in peripheral PYY3-36-induced feeding reduction in rats. Endocrinology 2005, 23:305-321.
48. Allison S.J., Baldock P., Sainsbury A., Enriquez R., Lee N.J., Lin E.J., et al. Conditional deletion of hypothalamic Y2 receptors reverts gonadectomy-induced bone loss in adult mice. J Biol Chem 2006, 281:23436-23444.
49. Baldock P., Sainsbury A., Couzens M., Enriquez R., Ghomas G.P., Gardiner E.M., et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 2002, 109:915-921.
50. Shi Y.C., Lin S., Wong I.P., Baldock P.A., Aljanova A., Enriquez R.F., et al. NPY neuron-specific Y2 receptors regulate adipose tissue and trabecular bone but not cortical bone homeostasis in mice. PLoS One 2010, 5:e11361.
51. Dumont Y., Fournier A., St-Pierre S., Schwartz T.W., Quirion R. Differential distribution of neuropeptide Y1 and Y2 receptors in the rat brain. Eur J Pharmacol 1990, 191:501-503.
52. Igwe J.C., Jiang X., Paic F., Ma L., Adams D.J., Baldock P.A., et al. Neuropeptide Y is expressed by osteocytes and can inhibit osteoblastic activity. J Cell Biochem 2009, 108:621-630.
53. Lundberg J.M., Martinsson A., Hemsen A., Theodorsson-Norheim E., Svendenhag J., Ekblom B., et al. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun 1985, 133:30-36.
54. Kempna P., Korner M., Waser B., Hofer G., Nuoffer J.M., Reubi J.C., et al. Neuropeptide Y modulates steroid production of human adrenal H295R cells through Y1 receptors. Mol Cell Endocrinol 2010, 314:101-109.
55. Morgan D.G., Kulkarni R.N., Hurley J.D., Wang Z.L., Wang R.M., Ghatei M.A., et al. Inhibition of glucose stimulated insulin secretion by neuropeptide Y is mediated via the Y1 receptor and inhibition of adenylyl cyclase in RIN 5AH rat insulinoma cells. Diabetologia 1998, 41:1482-1491.
56. Bjurholm A. Neuroendocrine peptides in bone. Int Orthop 1991, 15:325-329.
57. Bjurholm A., Kreicbergs A., Schultzberg M., Lerner U.H. Neuroendocrine regulation of cyclic AMP formation in osteoblastic cell lines (UMR-106-01, ROS 17/2.8, MC3T3-E1, and Saos-2) and primary bone cells. J Bone Miner Res 1992, 7:1011-1019.
58. Amano S., Arai M., Goto S., Togari A. Inhibitory effect of NPY on isoprenaline-induced osteoclastogenesis in mouse bone marrow cells. Biochim Biophys Acta 2007, 1770:966-973.
59. Rodriguez E.M., Blazquez J.L., Guerra M. The design of barriers in the hypothalamus allows the median eminence and the arcuate nucleus to enjoy private milieus: the former opens to the portal blood and the latter to the cerebrospinal fluid. Peptides 2010, 31:757-776.
60. Marks J.L., Wait K. Intracerebroventricular neuropeptide Y acutely influences glucose metabolism and insulin sensitivity in the rat. J Neuroendocrinol 1997, 9:99-103.
61. Willesen M.G., Kristensen P., Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999, 70:306-316.
62. Elmquist J.K., Maratos-Flier E., Saper C.B., Flier J.S. Unraveling the central nervous system pathways underlying responses to leptin. Nat Neurosci 1998, 1:445-450.
63. Dowell P., Hu Z., Lane M. Monitoring energy balance: metabolites of fatty acid synthesis as hypothalamic sensors. Annu Rev Biochem 2005, 74:515-534.
64. Beck B., Burlet A., Bazin R., Nicholas J.P., Burlet C. Elevated neuropeptide Y in the arcuate nucleus of young obese Zucker rats may contribute to the development of their overeating. J Nutr 1993, 123:1168-1172.
65. Kalra S.P., Dube M.G., Sahu A., Phelps C.P., Kalra P.S. Neuropeptide Y secretion increases in the paraventricular nucleus in association with increased appetite for food. Proc Natl Acad Sci U S A 1991, 88:10931-10935.
66. McKibbon P.E., Cotton S.J., McMillan S., Holloway B., Mayers R., McCarthy H.D., et al. Altered neuropeptide Y concentrations in specific hypothalamic regions of obese (fa/fa) Zucker rats. Possible relationship to obesity and neuroendocrine disturbances. Diabetes 1991, 40:1423-1429.
67. Williams G., Steel J.H., Cardoso H., Ghatei M.A., Lee Y.C., Gill J.S., et al. Increased hypothalamic neuropeptide Y concentrations in diabetic rat. Diabetes 1988, 37:763-772.
68. Baldock P.A., Sainsbury A., Allison S., Lin E.J., Couzens M., Boey D., et al. Hypothalamic control of bone formation: distinct actions of leptin and Y2 receptor pathways. J Bone Miner Res 2005, 20:1851-1857.
69. Billington C.J., Briggs J.E., Harker S., Grace M., Levine A.S. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy metabolism. Am J Physiol 1994, 266:R1765-R1770.
70. Pierroz D.D., Catzeflis C., Aebi A.C., Rivier J.E., Aubert M.L. Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology 1996, 137:3-12.
71. Sainsbury A., Rohner-Jeanrenaud F., Cusin I., Zakrzewska K.E., Halban P.A., Gaillard R.C., et al. Chronic central neuropeptide Y infusion in normal rats: status of the hypothalamo-pituitary-adrenal axis, and vagal mediation of hyperinsulinaemia. Diabetologia 1997, 40:1269-1277.
72. Zarjevski N., Cusin I., Vettor R., Rohner-Jeanrenaud F., Jeanrenaud B. Intracerebroventricular administration of neuropeptide Y to normal rats has divergent effects on glucose utilization by adipose tissue and skeletal muscle. Diabetes 1994, 43:764-769.
73. Wahlestedt C., Skagerberg G., Ekman R., Heilig M., Sundler F., Hakanson R. Neuropeptide Y (NPY) in the area of the hypothalamic paraventricular nucleus activates the pituitary-adrenocortical axis in the rat. Brain Res 1987, 417:33-38.
74. Leibowitz S.F., Sladek C., Spencer L., Tempel D. Neuropeptide Y, epinephrine and norepinephrine in the paraventricular nucleus: stimulation of feeding and the release of corticosterone, vasopressin and glucose. Brain Res Bull 1988, 21:905-912.
75. Small C.J., Morgan D.G., Meeran K., Heath M.M., Gunn I., Edwards C.M., et al. Peptide analogue studies of the hypothalamic neuropeptide Y receptor mediating pituitary adrenocorticotrophic hormone release. Proc Natl Acad Sci U S A 1997, 94:11686-11691.
76. Harfstrand A., Eneroth P., Agnati L., Fuxe K. Further studies on the effects of central administration of neuropeptide Y on neuroendocrine function in the male rat: relationship to hypothalamic catecholamines. Regul Pept 1987, 17:167-179.
77. Catzeflis C., Pierroz D.D., Rohner-Jeanrenaud F., Rivier J.E., Sizonenko P.C., Aubert M.L. Neuropeptide Y administered chronically into the lateral ventricle profoundly inhibits both the gonadotropic and the somatotropic axis in intact adult female rats. Endocrinology 1993, 132:224-234.
78. Pierroz D.D., Catzeflis C., Aebi A.C., Rivier J.E., Aubert M.L. Chronic administration of neuropeptide Y into the lateral ventricle inhibits both the pituitary-testicular axis and growth hormone and insulin-like growth factor I secretion in intact adult male rats. Endocrinology 1996, 137:3-12.
79. Billington C.J., Briggs J.E., Grace M., Levine A.S. Effects of intracerebroventricular injection of neuropeptide Y on energy metabolism. Am J Physiol 1991, 260:R321-R327.
80. Szreder Z., Hori T., Kaizuka Y. Thermoregulatory effect of intracerebral injections of neuropeptide Y in rats at different environmental temperatures. Gen Pharmacol 1994, 25:85-91.
81. Currie P.J., Coscina D.V. Dissociated feeding and hypothermic effects of neuropeptide Y in the paraventricular and perifornical hypothalamus. Peptides 1995, 16:599-604.
82. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381:415-421.
83. Erickson J.C., Hollopeter G., Palmiter R.D. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996, 274:1704-1707.
84. Kushi A., Sasai H., Koizumi H., Takeda N., Yokoyama M., Nakamura M. Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor-deficient mice. Proc Natl Acad Sci U S A 1998, 95:15659-15664.
85. Pedrazzini T., Seydoux J., Kunstner P., Aubert J.F., Grouzmann E., Beermann F., et al. Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor. Nat Med 1998, 4:722-726.
86. Naveilhan P., Svensson L., Nystrom S., Ekstrand A.J., Ernfors P. Attenuation of hypercholesterolemia and hyperglycemia in ob/ob mice by NPY Y2 receptor ablation. Peptides 2002, 23:1087-1091.
87. Howell O.W., Scharfman H.E., Herzog H., Sundstrom L.E., Beck-Sickinger A., Gray W.P. Neuropeptide Y is neuroproliferative for post-natal hippocampal precursor cells. J Neurochem 2003, 86:646-659.
88. Kanatani A., Mashiko S., Murai N., Sugimoto N., Ito J., Fukuroda T., et al. Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice. Endocrinology 2000, 141:1011-1016.
89. Pralong F.P., Gonzales C., Voirol M.J., Palmiter R.D., Brunner H.R., Gaillard R.C., et al. The neuropeptide Y Y1 receptor regulates leptin-mediated control of energy homeostasis and reproductive functions. FASEB J 2002, 16:712-714.
90. Zhang L., Macia L., Turner N., Enriquez R.F., Riepler S.J., Nguyen A.D., et al. Peripheral neuropeptide Y Y1 receptors regulate lipid oxidation and fat accretion. Int J Obes (Lond) 2010, 34:357-373.
91. Sainsbury A., Bergen H.T., Boey D., Bamming D., Cooney G.J., Lin S., et al. Y2Y4 receptor double knockout protects against obesity due to a high-fat diet or Y1 receptor deficiency in mice. Diabetes 2006, 55:19-26.
92. Burcelin R., Brunner H., Seydoux J., Thorens B., Pedrazzini T. Increased insulin concentrations and glucose storage in neuropeptide Y Y1 receptor-deficient mice. Peptides 2001, 22:421-427.
93. Marsh D.J., Hollopeter G., Kafer K.E., Palmiter R.D. Role of the Y5 neuropeptide Y receptor in feeding and obesity. Nat Med 1998, 4:718-721.
94. Iyengar S., Li D.L., Simmons R.M. Characterization of neuropeptide Y-induced feeding in mice: do Y1-Y6 receptor subtypes mediate feeding?. J Pharmacol Exp Ther 1999, 289:1031-1040.
95. Higuchi H., Niki T., Shiiya T. Feeding behavior and gene expression of appetite-related neuropeptides in mice lacking for neuropeptide Y Y5 receptor subclass. World J Gastroenterol 2008, 14:6312-6317.
96. Herzog H., Darby K., Ball H., Hort Y., Beck-Sickinger A., Shine J. Overlapping gene structure of the human neuropeptide Y receptor subtypes Y1 and Y5 suggests coordinate transcriptional regulation. Genomics 1997, 41:315-319.
97. Wolak M.L., DeJoseph M.R., Cator A.D., Mokashi A.S., Brownfield M.S., Urban J.H. Comparative distribution of neuropeptide Y Y1 and Y5 receptors in the rat brain by using immunohistochemistry. J Comp Neurol 2003, 464:285-311.
98. Labelle M., Boulanger Y., Fournier A., St Pierre S., Savard S. Tissue-specific regulation of fat cell lipolysis by NPY in 7-OHDA-treated rats. Peptides 1997, 18:801-808.
99. Serradeil-Le Gal C., Lafontan M., Raufaste D., Marchand J., Pouzet B., Casellas P., et al. Characterization of NPY receptors controlling lipolysis and leptin secretion in human adipocytes. FEBS Lett 2000, 475:150-156.
100. Sainsbury A., Schwarzer C., Couzens M., Herzog H. Y2 receptor deletion attenuates the type 2 diabetic syndrome of ob/ob mice. Diabetes 2002, 51:3420-3427.
101. Ducy P., Amling M., Takeda S., Priemel M., Schilling A.F., Beil F.T., et al. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 2000, 100:197-207.
102. Sipols A.J., Baskin D.G., Schwartz M.W. Effect of intracerebroventricular insulin infusion on diabetic hyperphagia and hypothalamic neuropeptide gene expression. Diabetes 1995, 44:147-151.
103. Zengin A., Zhang L., Herzog H., Baldock P.A., Sainsbury A. Neuropeptide Y and sex hormone interactions in humoral and neuronal regulation of bone and fat. Trends Endocrinol Metab 2010, 21:411-418.